Scarica l'app Stockscreener
8.65
0.35%
-0.03
Dopo l'orario di chiusura:
8.69
0.04
+0.46%
Precedente Chiudi:
$8.68
Aprire:
$8.44
Volume 24 ore:
317.81K
Relative Volume:
0.90
Capitalizzazione di mercato:
$455.20M
Reddito:
-
Utile/perdita netta:
$-197.68M
Rapporto P/E:
-1.5175
EPS:
-5.7
Flusso di cassa netto:
$-158.88M
1 W Prestazione:
+2.13%
1M Prestazione:
+49.40%
6M Prestazione:
+243.25%
1 anno Prestazione:
+210.04%
Intervallo 1D:
$8.33
$8.95
Intervallo di 1 settimana:
$8.03
$9.55
Portata 52W:
$2.185
$11.60
Kodiak Sciences Inc Stock (KOD) Company Profile
Nome
Kodiak Sciences Inc
Settore
Industria
Telefono
650-281-0850
Indirizzo
1200 PAGE MILL RD, PALO ALTO, CA
Confronta KOD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
8.65 | 455.20M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-05 | Iniziato | H.C. Wainwright | Neutral |
| 2023-12-11 | Ripresa | Goldman | Sell |
| 2023-11-17 | Aggiornamento | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Downgrade | UBS | Buy → Neutral |
| 2023-07-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-15 | Iniziato | CapitalOne | Overweight |
| 2022-08-02 | Downgrade | Citigroup | Neutral → Sell |
| 2022-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Iniziato | Goldman | Buy |
| 2022-02-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Iniziato | Evercore ISI | Outperform |
| 2021-03-01 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-11-30 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-03 | Iniziato | Goldman | Buy |
| 2020-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Iniziato | SunTrust | Buy |
| 2020-01-08 | Iniziato | ROTH Capital | Buy |
| 2020-01-03 | Iniziato | Jefferies | Buy |
| 2019-12-24 | Iniziato | JP Morgan | Overweight |
| 2019-10-15 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-20 | Iniziato | Chardan Capital Markets | Buy |
| 2018-10-29 | Iniziato | Barclays | Overweight |
| 2018-10-29 | Iniziato | BofA/Merrill | Buy |
| 2018-10-29 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Kodiak Sciences Inc Borsa (KOD) Ultime notizie
Kodiak Sciences Inc. (NASDAQ:KOD) Shares Bought by Fmr LLC - Defense World
Kodiak Sciences' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com South Africa
Kodiak Sciences' SWOT analysis: biotech stock faces pivotal year ahead - Investing.com India
Critical Survey: Allogene Therapeutics (NASDAQ:ALLO) versus Kodiak Sciences (NASDAQ:KOD) - Defense World
Nona Biosciences and Kodiak Sciences Partner on Next-Generation Antibody Therapies for Ophthalmic Diseases - The Eastern Progress Online
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Simply Wall St
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential - MSN
Nona Biosciences Partners With Kodiak Sciences For Ophthalmic Antibody Discovery - Contract Pharma
Nona Biosciences and Kodiak Sciences Inc. Partners on Next-Generation Antibody Therapies for Ophthalmic Diseases - Marketscreener.com
Nona Biosciences, Kodiak Sciences partner on antibody therapies for ophthalmic diseases - Seeking Alpha
Kodiak Sciences Partners with Nona Biosciences for Novel Eye Disease Antibody Development - StockTitan
Jefferies Upgrades Kodiak Sciences (KOD) - MSN
Kodiak stock rallies 32% after Jefferies upgrades to buy - MSN
Pactiv Evergreen, RealReal, Kodiak Sciences And Other Big Stocks Moving Higher On Monday - Benzinga
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock - Yahoo Finance
Kodiak Sciences shares initiated with buy rating on positive outlook By Investing.com - Investing.com South Africa
Kodiak stock rallies 32% after Jefferies upgrades to buy (NASDAQ:KOD) - Seeking Alpha
Kodiak Sciences shares initiated with buy rating on positive outlook - Investing.com
Kodiak Sciences (NASDAQ:KOD) Upgraded to "Buy" at Jefferies Financial Group - MarketBeat
Jacobs Levy Equity Management Inc. Sells 118,375 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - MarketBeat
Kodiak Sciences stock hits 52-week high at $7.81 By Investing.com - Investing.com Canada
Kodiak Sciences stock hits 52-week high at $7.81 - Investing.com India
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Kodiak Sciences' SWOT analysis: biotech firm's stock faces pivotal trials - Investing.com
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
GSA Capital Partners LLP Makes New Investment in Kodiak Sciences Inc. (NASDAQ:KOD) - MarketBeat
Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade) - Seeking Alpha
Kodiak Sciences (NASDAQ:KOD) Given New $4.00 Price Target at Barclays - MarketBeat
Kodiak Sciences Inc (KOD) Quarterly 10-Q Report - Quartzy
Kodiak Sciences: Drug Shows 3x Longer Half-Life, Reports $43.9M Q3 Loss | KOD Stock News - StockTitan
Diabetic Retinopathy Clinical Trials 2024: FDA Approvals, - openPR
Kodiak Sciences to Present at Two Major Healthcare Investor Conferences | KOD Stock News - StockTitan
Report Finds Big Disparities in Americans' Well-Being by Region - 69News WFMZ-TV
Weight Loss Meds Help Stroke Survivors Prevent Stroke Recurrence, Death - 69News WFMZ-TV
Diabetes & Kidney Trouble Can Bring Heart Disease Decades Earlier - 69News WFMZ-TV
Hourglass-Shaped Stent Might Ease Tough-to-Treat Angina - 69News WFMZ-TV
Bystanders More Readily Perform CPR If 911 Operator Instructs - 69News WFMZ-TV
How ADHD May Influence a Child's Weight - 69News WFMZ-TV
Have an Implanted Defibrillator? Triple-Digit Heatwaves Could Pose Danger - 69News WFMZ-TV
Obesity-Linked Heart Deaths Nearly Tripled in U.S. Over Past Two Decades - 69News WFMZ-TV
Empowering Growth: Diabetic Macular Edema Market 2024 - openPR
Age-Related Macular Degeneration Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight - Barchart
Bow-legged girl 14 cm taller after life-changing surgery - 69News WFMZ-TV
Kodiak Sciences (KOD) Price Target Increased by 25.00% to 5.10 - MSN
Zacks Research Raises Earnings Estimates for Kodiak Sciences - MarketBeat
Age-related Macular Degeneration Market Size is Set for Rapid - openPR
Sanctuary Advisors LLC Purchases New Holdings in Denny’s Co. (NASDAQ:DENN) - Defense World
Kodiak Sciences Inc Azioni (KOD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kodiak Sciences Inc Azioni (KOD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BORGESON JOHN A. | See Remarks |
Jun 12 '24 |
Sale |
2.92 |
1,558 |
4,549 |
179,544 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):